Several randomized controlled trials have demonstrated the benefits of glucagon-like
peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this …

Diabetes mellitus (DM) is a chronic illness with an increasing global prevalence. More than
537 million cases of diabetes were reported worldwide in 2021, and the number is steadily …

Diabetes is a chronic metabolic disease, and its therapeutic goals focus on the effective
management of blood glucose and various complications. Drug combination therapy has …

Skeletal muscle (SM) plays a vital role in energy and glucose metabolism by regulating
insulin sensitivity, glucose uptake, and blood glucose homeostasis. Impaired SM …

Obesity is a growing civilization problem, associated with a number of negative health
consequences affecting almost all tissues and organs. Currently, obesity treatment includes …

Simple Summary Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were drugs
originally intended for the management of diabetes, while their role on the treatment of …

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising
therapeutic agents with potent anti-inflammatory properties and diverse clinical implications …

Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially for type 2
diabetes mellitus, show promise in promoting weight loss and improving heart health in …

Over the past 4 decades, research has shown that having a normal body weight does not
automatically imply preserved metabolic health and a considerable number of lean …

The obesity epidemic in the United States continues to grow with more than 40% of
individuals now classified as obese (body mass index> 30). Obesity has been readily …